Waters Corporation (WAT) – An Attractive Entry Point in Life Sciences
Waters Corporation has pulled back meaningfully following its first-quarter results, and we think that selloff has created an attractive entry point into one of the highest-quality franchises in life sciences instrumentation. The combination of a strong core replacement cycle, idiosyncratic growth drivers over the next several years, and the transformative BD Biosciences and Diagnostic Solutions acquisition positions WAT for a sustained period of above-market earnings growth. We rate the stock a Buy at US$297.80 with a 12-month price target of US$375, representing 25.9% upside.
Research published 1 April 2026. Price target and upside based on prices at time of publication.
About Waters Corporation
Waters Corporation is a leading global provider of analytical instruments, software, and consumables for life sciences, pharmaceutical, and industrial markets. Headquartered in Milford, Massachusetts, Waters is best known for its leadership in liquid chromatography (LC) and mass spectrometry (MS), which are essential tools for drug development, quality control, environmental testing, and food safety analysis. The company also has a significant thermal analysis business through its TA Instruments division. Waters recently completed the acquisition of Becton Dickinson’s Biosciences and Diagnostic Solutions business, adding flow cytometry and microbiology diagnostics to its portfolio. WAT has a market capitalisation of approximately US$29.4 billion and an enterprise value of US$29.2 billion.
Why the Selloff Creates an Opportunity
The thesis here is straightforward. WAT’s stock came under pressure following 1Q26 results that included softer-than-expected performance from the newly acquired BD assets. The market reaction was sharp, but we think it was overdone. The underperformance in the BD business was driven by transient factors rather than structural issues, and the selloff has created a more attractive baseline for investors looking to enter a high-quality life sciences name.
When a company with Waters’ track record sells off on near-term noise in a recently closed acquisition, history suggests it tends to be an opportunity rather than a warning sign. The core Waters business continues to perform well, and the BD integration is still in its early stages with significant value creation ahead.
Core Business Benefiting From Replacement Cycle
Waters’ core liquid chromatography and mass spectrometry business is benefiting from an ongoing instrument replacement cycle that has several years to run. The installed base of LC and MS instruments across pharmaceutical and biotech laboratories is ageing, and customers are increasingly upgrading to newer platforms that offer improved sensitivity, throughput, and data quality.
Several factors support continued momentum in the core business:
- The pharmaceutical R&D spending environment remains healthy, with large pharma and biotech companies investing in analytical capabilities to support growing pipelines
- Regulatory requirements continue to tighten globally, driving demand for more sophisticated analytical instruments in quality control and compliance applications
- Waters’ newest instrument platforms offer meaningful performance improvements over prior generations, giving customers a strong reason to upgrade rather than extend the life of existing equipment
- The consumables and service revenue attached to each installed instrument creates a recurring revenue stream that grows as the installed base expands
Beyond the replacement cycle, Waters has several idiosyncratic growth drivers that should support above-market growth over the next few years. These include expanding applications in biologics characterisation, growing demand in food and environmental testing, and new product launches that address emerging analytical challenges in cell and gene therapy manufacturing.
The BD Acquisition Adds Scale and Diversification
The acquisition of Becton Dickinson’s Biosciences and Diagnostic Solutions business is transformative for Waters. It brings two important capabilities into the portfolio: flow cytometry (clinical market leader with the FACSLyric platform) and microbiology diagnostics.
Flow cytometry is a critical technology in clinical diagnostics and pharmaceutical research. BD’s FACSLyric platform is the market leader in clinical flow cytometry, and the installed base creates significant stickiness, particularly in clinical and midstream pharma applications where switching costs are high and regulatory validation requirements make it difficult to change platforms. This is exactly the kind of recurring, high-margin revenue stream that complements Waters’ existing business model.
The microbiology diagnostics business adds a further dimension, giving Waters exposure to the clinical diagnostics market and diversifying the revenue base beyond purely analytical instrumentation. While this business was part of what underperformed in 1Q26, the long-term fundamentals remain intact.
We see a meaningful pricing power opportunity in the BD assets. The installed base creates natural lock-in, and Waters’ track record of extracting value from instrument-consumable-service business models should translate well to the flow cytometry franchise. Goldman Sachs research supports the view that the 1Q26 weakness is a baseline reset rather than a structural concern.
Financial Summary
The BD acquisition creates a step change in Waters’ financial profile starting in FY26. Revenue roughly doubles, and while margins compress temporarily during integration, the trajectory toward margin recovery and expansion is clear:
- Revenue: 12/25 US$3,165m, 12/26E US$6,437m, 12/27E US$7,149m, 12/28E US$7,595m
- EPS: 12/25 US$13.13, 12/26E US$14.39, 12/27E US$16.30, 12/28E US$18.26
- PE ratio: 12/25 26.6x, 12/26E 20.7x, 12/27E 18.3x, 12/28E 16.3x
- EBITDA: 12/25 US$1,170m, 12/26E US$2,214m, 12/27E US$2,509m, 12/28E US$2,750m
- EBITDA margin: 12/25 37.0%, 12/28E 36.2%
- Free cash flow: 12/25 US$540m, 12/26E US$926m, 12/27E US$1,639m, 12/28E US$1,922m
The EPS trajectory from US$13.13 in 2025 to US$18.26 by 2028 represents a compound annual growth rate of approximately 12%, which is attractive for a life sciences tools company at a sub-21x forward PE. The free cash flow ramp is particularly notable, growing from US$540 million pre-acquisition to nearly US$1.9 billion by 2028 as integration costs roll off and the combined business achieves scale efficiencies.
EBITDA margins compress slightly in the near term as BD assets are integrated, but the path back toward and beyond pre-deal levels is supported by cost synergies, pricing initiatives, and mix improvements as higher-margin consumables and service revenue grows relative to instrument sales.
Instrument-Consumable-Service Flywheel
One of the reasons Waters commands premium multiples in the life sciences tools space is the quality of its business model. Every instrument placed in a laboratory generates years of recurring consumable and service revenue. The razors-and-blades dynamic means that the installed base is a compounding asset, with each new placement adding to the long-term revenue stream.
The BD acquisition amplifies this flywheel. Flow cytometry instruments, like LC and MS systems, require ongoing reagent purchases and service contracts. The clinical setting adds an extra layer of stickiness because instrument validation requirements make switching costly and disruptive. As Waters integrates the BD assets and applies its proven commercial playbook, we expect the recurring revenue component of the combined business to grow as a percentage of total revenue.
Valuation and Price Target
The US$375 price target reflects a reinstated Buy rating following the 1Q26 selloff. At US$297.80, WAT trades at 20.7x FY26E earnings, which is below its historical average and below the life sciences tools peer group. We think this discount is unwarranted given the quality of the franchise, the earnings growth trajectory, and the free cash flow ramp over the next three years.
The 25.9% upside to the price target is supported by both earnings growth and multiple expansion as the market gains confidence in the BD integration and the combined business demonstrates its full earnings potential. The PE multiple compresses to 16.3x by 2028, which would represent a historically cheap entry point for a business of this quality.
Risks to Watch
Integration execution is the primary risk. The BD acquisition is the largest in Waters’ history, and large-scale integrations can encounter unexpected challenges in combining sales forces, harmonising product lines, and retaining key talent. If the BD assets continue to underperform, the market may question the strategic rationale and apply a further discount.
The pharmaceutical spending environment is cyclical. While current trends are supportive, a pullback in pharma R&D budgets would weigh on both instrument sales and the broader life sciences tools sector. Waters’ exposure to China, while manageable, introduces geopolitical risk that could impact demand in that region.
Balance sheet leverage is elevated post-acquisition. While free cash flow generation supports deleveraging over time, any significant operational shortfall could slow the pace of debt reduction and limit capital allocation flexibility. The company needs to demonstrate that the BD assets can deliver the revenue and margin trajectory that justified the acquisition price, and any further quarters of underperformance would increase market scepticism.
Currency risk is also worth monitoring. Waters has significant international revenue exposure, and a strengthening US dollar would create translation headwinds on reported results. While the underlying business may be performing well in local currency terms, FX movements can obscure the fundamental trajectory and weigh on the stock in the near term.
Our View
Waters Corporation is a high-quality life sciences tools business that is temporarily trading at a discount to its intrinsic value. The 1Q26 selloff related to BD asset underperformance has created what we believe is an attractive entry point for investors who can look through near-term integration noise and focus on the multi-year earnings and free cash flow trajectory. The core business is healthy, the replacement cycle has years to run, and the BD acquisition brings scale, diversification, and a valuable recurring revenue stream. At 20.7x forward earnings with a clear path to mid-teens PE by 2028, we think the risk-reward is compelling.
If you would like to discuss Waters Corporation or how US equities might fit within your portfolio, request a callback or call us on 1300 889 603.
